ALZ — Alzinova AB Share News
0.000.00%
Last trade - 00:00- SEK148.49m
- SEK135.99m
Brief: Alzinova Initiates Development Of A Stable Cell Line To Prepare The Monoclonal Antibody Alz-201 For Alzheimer's Clinical Trials
Brief: Alzinova Announces Positive Safety Review And Continuation Of Its Phase 1B Study In Alzheimer's Disease
Brief: Alzinova Resolves On Rights Issue Of Units Of SEK 42.5 Mln
Brief: Alzinova Q1 Pretax Loss Widens To SEK 2.3 Million
Brief: Alzinova Q4 Pretax Loss Widens To SEK 2.5 Million
Brief: Alzinova To Receive Proceeds Of SEK 2.8 Mln
Brief: Alzinova Says Preclinical Data Confirms Specificity, Efficacy Of ALZ-201
Brief: Alzinova Q3 Loss After Financial Items Widens To SEK 1.5 Mln
Brief: Alzinova receives approval to start first clinical study with ALZ-101 vaccine in patients with Alzheimer's disease
Brief: Alzinova Q2 Loss After Financial Items Widens To SEK 2.2 Mln
Brief: Alzinova Q2 Pretax Loss Widens To SEK 2.2 Mln
Brief: Alzinova Q1 Pre-Tax Loss Narrows To SEK 1.5 Mln
Brief: Alzinova: Status Update Regarding Application To Start Clinical Study With ALZ-101
Brief: Alzinova Q4 Pretax Loss Narrows To SEK 2.4 Mln
Brief: Alzinova: Drug Substance For ALZ-101 Vaccine Meets Requirements Of Upcoming Clinical Phase 1B Study
Brief: Alzinova Announces Upcoming Clinical Study With Vaccine Candidate ALZ-101
Brief: Alzinova Q3 Pretax Loss Widens To Sek 1.2 Million
Brief: Alzinova Says Rights Issue Heavily Oversubscribed
Brief: Alzinova Gets Positive Feedback From Finnish Medicines Agency Fimea